NICE backs Akcea’s Tegsedi; EMA restricts Lemtrada use while it probes safety concerns

UK’s NICE has endorsed the use of Akcea’s inotersen (branded as Tegsedi) to treat patients with a rare inherited condition called hereditary transthyretin-related amyloidosis (hATTR), after the Ionis $IONS sister company offered the agency an “improved commercial agreement.” This counts as a win for Akcea, which has been competing against Alnylam’s $ALNY Onpattro, although the dataset supporting its approval is seen as a runner up to Onpattro. The UK has roughly 150 hATTR patients, according to NICE.

Last week, the EMA asked doctors to limit the use of Sanofi’s $SNY Lemtrada to adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies or in patients that cannot take any other treatments. The health regulator is restricting the drug’s use while it investigates reports of immune-mediated conditions and problems with the heart and blood vessels with the medicine, including fatal cases.

→ Charles River Laboratories $CRL and the CHDI Foundation have extended their long running alliance on Huntington’s disease by another 5 years, they said last week. They initially began work together back in 2005 and are now adding multidisciplinary activities to the pact.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->